The company is moving forward in working with early adopters in a limited setting of lung cancer testing, but still plans to expand its test to other cancers soon.
The partnership is part of a broader agreement between Genome BC and Genomics England to share data and tools around cancer and rare and infectious diseases.
The researchers designed a synthetic DNA method to be used as internal controls for NGS assays that could be applied to oncology, metagenomics, and immunology.
The European Molecular Genetics Quality Network, a provider of proficiency testing services for clinical genetics and molecular pathology labs, and its UK partner have been developing a new assessment scheme for NGS labs.
The company presented its findings last week at the 2016 Gastrointestinal Cancer Symposium and is preparing to launch the assay in the US later this year.
Novacyt will validate its Novaprep liquid-based cytology platform with Abbott's RealTime High Risk human papillomavirus assay.
The International Thyroid Congress and Annual Meeting of the American Thyroid Association announced studies validating diagnostics tests for several companies.
The company demonstrated high analytical sensitivity and specificity, and also showed clinical data supporting a high concordance with tumor tissue sequencing.
The partners will run several studies to validate the use of the MyPRS test in informing disease management in patients with multiple myeloma and its precursors.
In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.
The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.
Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.
Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.